explore -WSS

explore

author：comprehensive 2025-08-26 07:42:33 - browse：4888

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

hotspot

explore

WSS

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

The Biogen Aduhelm mess could happen again

Childhood vaccination ad campaign launches in the U.K.

340B reform proposal comes out of Senate working group

340B reform proposal comes out of Senate working group

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

focus

explore

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Virtual repurposing can help discover new uses for existing drugs

Malaria cases in Florida and Texas: Here’s what you need to know

Adopting new red light myopia treatments may be short

Sports medicine is finally prioritizing gender equality

The CDC's new social media misinformation war

Affirmative action in medical school literally saved lives

Doctor of U.S. President Joe Biden says he is fit for duty

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Devoted Health’s losses in Medicare Advantage persist

entertainment

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Color Health wants to make cancer screenings convenient

A single Democrat is willing to weaken Medicare negotiation power

Cholera vaccine supplies dangerously low, outbreaks surging

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

STAT Madness 2024: Meet the contenders

focus

hotspot

explore

hotspot